HighTower Advisors’s Vanda Pharmaceuticals VNDA Stock Holding History

HighTower Advisors’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-7,490	Closed	-$37.4K	–	3994
2025 Q3	$37.4K	Buy	7,490 +1,509	+25%	+$6.99K	﹤0.01%	3630
2025 Q2	$28.2K	Sell	5,981 -505	-8%	-$2.21K	﹤0.01%	3590
2025 Q1	$29.8K	Sell	6,486 -5,012	-44%	-$23.4K	﹤0.01%	3493
2024 Q4	$55.1K	Buy	11,498 +6,017	+110%	+$28.9K	﹤0.01%	3447
2024 Q3	$26K	Sell	5,481 -999	-15%	-$5.36K	﹤0.01%	3488
2024 Q2	$37K	Buy	+6,480	New	+$33.5K	﹤0.01%	3339
2024 Q1	–	Sell	-73,750	Closed	-$315K	–	4038
2023 Q4	$315K	Buy	73,750 +5,532	+8%	+$22.3K	﹤0.01%	2672
2023 Q3	$298K	Buy	68,218 +55,955	+456%	+$311K	﹤0.01%	2604
2023 Q2	$80K	Buy	+12,263	New	+$78.6K	﹤0.01%	3114
2019 Q1	–	Sell	-9,539	Closed	-$249K	–	2435
2018 Q4	$249K	Sell	9,539 -113	-1%	-$2.66K	﹤0.01%	1710
2018 Q3	$221K	Buy	+9,652	New	+$197K	﹤0.01%	1899

Other funds holding VNDA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

KAM

Krensavage Asset Management New York $263M AUM 66.99% 1-Year Est. Return

HighTower Advisors's VNDA Position: Q4 2025 in Review

HighTower Advisors sold out of Vanda Pharmaceuticals (VNDA) in Q4 2025, closing a stake of 7,490 shares — an estimated $37.4K sold.

HighTower Advisors first reported a position in VNDA in Q3 2018 and held it in 11 quarters. The position peaked at $315K in Q4 2023. 153 funds tracked by Wall St. Rank hold VNDA as of Q4 2025.

HighTower Advisors reported no remaining Vanda Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
HighTower Advisors sold 7,490 Vanda Pharmaceuticals shares in Q4 2025, an estimated $37.4K.
HighTower Advisors first reported a position in Vanda Pharmaceuticals in Q3 2018 and held it in 11 quarters.
HighTower Advisors's Vanda Pharmaceuticals position peaked at $315K in Q4 2023.
153 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q4 2025.

Based on HighTower Advisors's 13F filing for Q4 2025, filed 6 Feb 2026.